House’s $7.8B COVID-19 spending bill includes price assurances

A COVID-19 spending bill passed by the U.S. House of Representatives Wednesday would require that companies provide a “fair and reasonable” price for countermeasures sold to the government. The biopharma industry has strongly opposed attaching pricing provisions to government-funded R&D.

The supplemental spending bill seeks to appropriate $7.8 billion, a substantial increase from the $1.8 billion the Trump administration requested. ...